<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03786107</url>
  </required_header>
  <id_info>
    <org_study_id>PUMA-NER-9501</org_study_id>
    <nct_id>NCT03786107</nct_id>
  </id_info>
  <brief_title>HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib</brief_title>
  <official_title>HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puma Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puma Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, observational genomic screening protocol to identify participants
      whose tumors harbor somatic mutations in the ERBB2 (HER2) gene, as measured in circulating
      tumor DNA (ctDNA) . Participants with histologically confirmed, hormone receptor positive,
      HER-2 negative, metastatic breast cancer (MBC) or metastatic cervical cancer (MCC) are
      eligible for screening at 6 months intervals, or if disease progression is
      suspected/confirmed. Blood samples will be collected from eligible participants and ctDNA
      will be extracted and sequenced at a central laboratory, using a HER2-targeted next
      generation sequencing (NGS) test. A certified molecular test report will be issued from the
      central laboratory and provided to the investigators and the study sponsor. Participants who
      are identified with HER2 mutations by this screening protocol will subsequently have access
      to an appropriate neratinib treatment protocol, pending medical eligibility.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Eligible for Neratinib Treatment</measure>
    <time_frame>From enrollment date to identification of HER2 positive mutation, assessed up to five years</time_frame>
    <description>Identification of participants with somatic, activating HER2 mutations who might qualify for enrollment into neratinib treatment protocols</description>
  </primary_outcome>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer</condition>
  <condition>Metastatic Cervical Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Almac HER-Seq Assay</intervention_name>
    <description>whole blood sample analysis</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Circulating tumor DNA from plasma will be collected from eligible participants. ERBB2 (HER2)
      gene exons 8 and 17-24 will be sequenced by next generation sequencing (NGS) at a central
      laboratory.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with histologically-confirmed metastatic breast or metastatic cervical cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and men who are ≥18 years old at signing of informed consent

          -  Eastern Cooperative Oncology Group (ECOG) status of 0 to 2

          -  Provide written informed consent to participate in the study and for circulating tumor
             DNA screening

          -  Must be able to provide blood sample(s) for HER2 mutation testing

          -  Participants with imaging or histologically confirmed, HR-positive, HER2-negative MBC
             who are presently receiving or have received CDK4/6 inhibitor as a prior therapy in
             any setting, or participants with imaging or histologically confirmed metastatic
             cervical cancer

          -  At least one measurable lesion, as defined by RECIST v1.1

        Exclusion Criteria:

          -  Participants with breast cancer with known HER2-positive or HER2-amplified tumors

          -  Participants with breast cancer with HR-negative tumors

          -  Participants who have received HER2-directed TKI

          -  Participants with previously documented somatic KRAS activating mutation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Chief Medical and Scientific Officer</last_name>
    <role>Study Director</role>
    <affiliation>Puma Biotechnology, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Puma Biotechnology Clinical Operations Senior Director</last_name>
    <phone>(424) 248-6500</phone>
    <email>HER-Seq@pumabiotechnology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Wilton</city>
        <state>Cork</state>
        <zip>T12 DC4A</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Elm Park</city>
        <state>Dublin</state>
        <zip>D04 T6F4</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital, Institute for Cancer Research</name>
      <address>
        <city>Dublin</city>
        <zip>D07 R2WY</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital, Cancer Clinical Trials &amp; Research Unit</name>
      <address>
        <city>Dublin</city>
        <zip>D09 V2N0</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Waterford, Department of Medical Oncology</name>
      <address>
        <city>Waterford</city>
        <zip>X91 ER8E</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Davidoff Cancer Center</name>
      <address>
        <city>Petah tikva</city>
        <state>Central</state>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Reẖovot</city>
        <state>Central</state>
        <zip>76101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute for Oncology and Radiology of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quirónsalud Madrid</name>
      <address>
        <city>Pozuelo de Alarcón</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Oncológico Dr. Rosell, Hospital Universitario Quirón Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid, Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto Valenciano de Oncológia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating Tumor DNA</keyword>
  <keyword>HER2</keyword>
  <keyword>Genomic Screening</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Breast</keyword>
  <keyword>Cervical</keyword>
  <keyword>ERBB2</keyword>
  <keyword>Mutation</keyword>
  <keyword>CDK4/6</keyword>
  <keyword>HR Positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

